Vor Biopharma (VOR) Change in Accured Expenses (2020 - 2026)

Vor Biopharma (VOR) has reported Change in Accured Expenses for 7 consecutive years, with -$9.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 562.78% year-over-year to -$9.1 million; the TTM figure through Mar 2026 stood at $3.2 million (down 4.39% YoY), while the FY2025 annual figure was $10.9 million, up 387.73% from the prior year.
• Change in Accured Expenses slipped to -$9.1 million in Q1 2026 per VOR's latest filing, from $6.2 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $6.2 million in Q4 2025 and bottomed at -$9.1 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged $472647.1 across 5 years, with a median of $485000.0 in 2024.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses soared 2200.0% — and 2024, when it sank 2720.45%.
• Vor Biopharma's Change in Accured Expenses stood at $1.7 million in 2022, then tumbled by 89.61% to $172000.0 in 2023, then surged by 2043.6% to $3.7 million in 2024, then jumped by 68.32% to $6.2 million in 2025, then sank by 246.63% to -$9.1 million in 2026.
• Business Quant data shows VOR's Change in Accured Expenses at -$9.1 million in Q1 2026, $6.2 million in Q4 2025, and $5.0 million in Q3 2025.